[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[S. 2061 Introduced in Senate (IS)]
<DOC>
119th CONGRESS
1st Session
S. 2061
To require the Interagency Working Group on Toxic Exposure to conduct
research on the diagnosis and treatment of health conditions of
descendants of individuals exposed to toxic substances while serving as
members of the Armed Forces, and for other purposes.
_______________________________________________________________________
IN THE SENATE OF THE UNITED STATES
June 12, 2025
Mr. Blumenthal (for himself and Mrs. Murray) introduced the following
bill; which was read twice and referred to the Committee on Veterans'
Affairs
_______________________________________________________________________
A BILL
To require the Interagency Working Group on Toxic Exposure to conduct
research on the diagnosis and treatment of health conditions of
descendants of individuals exposed to toxic substances while serving as
members of the Armed Forces, and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Molly R. Loomis Research for
Descendants of Toxic Exposed Veterans Act of 2025''.
SEC. 2. RESEARCH ON DIAGNOSIS AND TREATMENT OF HEALTH CONDITIONS OF
DESCENDANTS OF INDIVIDUALS EXPOSED TO TOXIC SUBSTANCES
WHILE SERVING IN ARMED FORCES.
(a) In General.--Subsection (b) of section 501 of the Sergeant
First Class Heath Robinson Honoring our Promise to Address
Comprehensive Toxics Act of 2022 (Public Law 117-168) is amended by
adding at the end the following new paragraph:
``(3) Establish Federal interagency task forces to conduct
collaborative research activities.''.
(b) Reporting.--Subsection (c) of such section is amended by
striking paragraphs (2) and (3) and inserting the following:
``(2) Not later than one year after the date of the
enactment of the Molly R. Loomis Research for Descendants of
Toxic Exposed Veterans Act of 2025--
``(A) a report containing a description of the
collaborative research activities identified by the
Working Group under subsection (b);
``(B) the findings of the members of the Working
Group with respect to the collaborative research
activities described in subparagraph (A); and
``(C) such recommendations as the Working Group may
have for legislative or administrative action to
improve collaborative research activities among the
members of the Working Group.
``(3) Not less frequently than annually during the five-
year period covered by the strategic plan developed under
subsection (b)--
``(A) a summary of the collaborative research
activities carried out by the members of the Working
Group and the findings of the members with respect to
such research activities;
``(B) a progress report on implementation of the
strategic plan developed by the Working Group under
subsection (b); and
``(C) such recommendations as the Working Group may
have for legislative or administrative action to
improve collaborative research activities among members
of the Working Group.''.
(c) Research Requirements.--Such section is amended--
(1) by redesignating subsections (c) through (e) as
subsections (d) through (f), respectively;
(2) in subsection (e), as redesignated by paragraph (1), by
striking ``under subsection (c)'' and inserting ``under
subsection (d)''; and
(3) by inserting after subsection (b) the following new
subsection (c):
``(c) Requirements Relating to Certain Research on Impacts to
Descendants.--Not later than 180 days after the date of the enactment
of the Molly R. Loomis Research for Descendants of Toxic Exposed
Veterans Act of 2025, the Working Group and the Agency for Toxic
Substances and Disease Registry shall--
``(1) establish an interagency task force to conduct
research on the diagnosis and treatment of health conditions of
descendants of toxic-exposed veteran (as defined in section 101
of title 38, United States Code); and
``(2) maintain a publicly available website with
information on the activities and findings of the Agency under
paragraph (1), including a review of all relevant data to
determine the strength of evidence for a positive association
between a health condition researched and a toxic exposure risk
activity (as defined in section 1710(e)(4) of title 38, United
States Code) based on the categories set forth under section
1173(c)(2) of title 38, United States Code.''.
<all>